CSPC Pharmaceutical Group Limited has announced a strategic research collaboration agreement with AstraZeneca, a global leader in biopharmaceuticals, to discover and develop novel oral small molecule candidates. The agreement will utilize CSPC's AI-driven, dual-engine efficient drug discovery platform to identify promising small molecules targeting multiple diseases. AstraZeneca will have the option to exclusively license the pre-clinical candidates for development, manufacturing, and commercialization worldwide. CSPC will receive an upfront payment of $110 million, with potential additional payments totaling up to $1,620 million for development milestones and $3,600 million for sales milestones, along with possible royalties based on annual net sales.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。